AstraZeneca's candidate helped more patients reach a state with no visible disease signs than a placebo and reduced signs of inflammation and scarring. The report gives no approval or sales results, but the trial findings support its drug-development work.
This gives AstraZeneca stronger evidence that the candidate may help patients, which supports its work on new treatments. The report does not say regulators approved the drug or that it has started bringing in sales.
Follow AstraZeneca (AZN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZN